Thermo Fisher Scientific Inc (TMO) Shares Sold by Hayek Kallen Investment Management

Hayek Kallen Investment Management decreased its stake in Thermo Fisher Scientific Inc (NYSE:TMO) by 2.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 24,927 shares of the medical research company’s stock after selling 614 shares during the period. Thermo Fisher Scientific makes up 3.2% of Hayek Kallen Investment Management’s portfolio, making the stock its 8th largest holding. Hayek Kallen Investment Management’s holdings in Thermo Fisher Scientific were worth $4,716,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in TMO. BlackRock Inc. grew its stake in shares of Thermo Fisher Scientific by 2,692.1% in the first quarter. BlackRock Inc. now owns 22,988,885 shares of the medical research company’s stock worth $3,531,095,000 after acquiring an additional 22,165,530 shares during the last quarter. Capital Research Global Investors grew its stake in shares of Thermo Fisher Scientific by 29.8% in the second quarter. Capital Research Global Investors now owns 17,304,897 shares of the medical research company’s stock worth $3,019,185,000 after acquiring an additional 3,973,136 shares during the last quarter. Janus Henderson Group PLC grew its stake in shares of Thermo Fisher Scientific by 2,058.1% in the second quarter. Janus Henderson Group PLC now owns 2,342,046 shares of the medical research company’s stock worth $408,620,000 after acquiring an additional 2,233,522 shares during the last quarter. Veritas Asset Management LLP grew its stake in shares of Thermo Fisher Scientific by 112.4% in the second quarter. Veritas Asset Management LLP now owns 2,430,759 shares of the medical research company’s stock worth $424,095,000 after acquiring an additional 1,286,259 shares during the last quarter. Finally, Harbour Capital Advisors LLC grew its stake in shares of Thermo Fisher Scientific by 18,197.5% in the second quarter. Harbour Capital Advisors LLC now owns 1,201,051 shares of the medical research company’s stock worth $6,884,000 after acquiring an additional 1,194,487 shares during the last quarter. Institutional investors and hedge funds own 83.78% of the company’s stock.

Thermo Fisher Scientific Inc (NYSE:TMO) opened at $190.17 on Friday. The stock has a market capitalization of $76,257.22, a price-to-earnings ratio of 20.90, a price-to-earnings-growth ratio of 1.74 and a beta of 1.08. Thermo Fisher Scientific Inc has a twelve month low of $139.07 and a twelve month high of $201.20. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.81 and a current ratio of 1.26.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, October 25th. The medical research company reported $2.31 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.24 by $0.07. The company had revenue of $5.12 billion during the quarter, compared to analysts’ expectations of $5.03 billion. Thermo Fisher Scientific had a return on equity of 15.94% and a net margin of 11.73%. The business’s revenue was up 13.9% on a year-over-year basis. During the same period last year, the business earned $2.03 earnings per share. equities research analysts anticipate that Thermo Fisher Scientific Inc will post 9.36 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, January 15th. Shareholders of record on Friday, December 15th will be issued a dividend of $0.15 per share. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.32%. Thermo Fisher Scientific’s payout ratio is presently 10.19%.

In related news, VP Seth H. Hoogasian sold 4,140 shares of Thermo Fisher Scientific stock in a transaction dated Monday, August 28th. The stock was sold at an average price of $177.80, for a total value of $736,092.00. Following the completion of the transaction, the vice president now directly owns 25,518 shares of the company’s stock, valued at $4,537,100.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Marc N. Casper sold 50,000 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $188.39, for a total value of $9,419,500.00. Following the completion of the transaction, the chief executive officer now directly owns 252,577 shares of the company’s stock, valued at $47,582,981.03. The disclosure for this sale can be found here. Over the last three months, insiders have sold 60,420 shares of company stock valued at $11,308,477. Company insiders own 0.49% of the company’s stock.

A number of research firms have weighed in on TMO. Cowen and Company reiterated an “outperform” rating and set a $220.00 price target (up previously from $200.00) on shares of Thermo Fisher Scientific in a research note on Sunday, September 10th. Leerink Swann lifted their price target on shares of Thermo Fisher Scientific from $190.00 to $207.00 and gave the stock an “outperform” rating in a research note on Monday, October 9th. Zacks Investment Research downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Monday, October 30th. Goldman Sachs Group, Inc. (The) began coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, September 26th. They set a “buy” rating and a $225.00 price target on the stock. Finally, Deutsche Bank AG set a $226.00 price target on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a research note on Thursday, October 26th. One investment analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $205.71.

ILLEGAL ACTIVITY WARNING: This news story was first reported by Transcript Daily and is owned by of Transcript Daily. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://transcriptdaily.com/2017/11/19/thermo-fisher-scientific-inc-tmo-shares-sold-by-hayek-kallen-investment-management.html.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply